NYSE:ADCT ADC Therapeutics (ADCT) Stock Price, News & Analysis $1.06 +0.02 (+1.43%) Closing price 06/15/2026 03:59 PM EasternExtended Trading$1.08 +0.02 (+1.41%) As of 06/15/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ADC Therapeutics Stock (NYSE:ADCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADC Therapeutics alerts:Sign Up Key Stats Today's Range$1.02▼$1.1050-Day Range$0.99▼$4.3952-Week Range$0.78▼$4.98Volume1.85 million shsAverage Volume2.89 million shsMarket Capitalization$135.46 millionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingHold Company Overview ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity. At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S. Food and Drug Administration for the treatment of adults with relapsed or refractory large B-cell lymphoma. In addition to this approved asset, the company’s pipeline features multiple next-generation ADC candidates targeting novel antigens, several of which are advancing through late-stage clinical trials. Founded in 2012 as a spin-out from Heidelberg University, ADC Therapeutics is headquartered in Lausanne, Switzerland, with additional offices in London and New York. Its global footprint spans Europe and North America, encompassing clinical research sites and manufacturing partnerships that support multi-regional trials and scaled production of its specialized conjugates. The company is led by a management team with deep expertise in antibody engineering, oncology drug development and regulatory affairs. Through collaborations with academic institutions and industry partners, ADC Therapeutics seeks to accelerate its translational research efforts and bring innovative ADC therapies to patients battling blood cancers.AI Generated. May Contain Errors. Read More ADC Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreADCT MarketRank™: ADC Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 597th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingADC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialADC Therapeutics has a consensus price target of $6.25, representing about 486.9% upside from its current price of $1.07.Amount of Analyst CoverageADC Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ADC Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ADC Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADC Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ADC Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.04% of the float of ADC Therapeutics has been sold short.Short Interest Ratio / Days to CoverADC Therapeutics has a short interest ratio ("days to cover") of 7.76.Change versus previous monthShort interest in ADC Therapeutics has recently increased by 5.58%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADC Therapeutics does not currently pay a dividend.Dividend GrowthADC Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News SentimentN/A News SentimentADC Therapeutics has a news sentiment score of -0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ADC Therapeutics this week, compared to 2 articles on an average week.Search Interest9 people have searched for ADCT on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows6 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ADC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,641,067.00 in company stock.Percentage Held by Insiders5.40% of the stock of ADC Therapeutics is held by insiders.Percentage Held by Institutions41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADC Therapeutics' insider trading history. Receive ADCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADCT Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCTJune 11, 2026 | prnewswire.comADC Therapeutics (ADCT) Is Down 69.7% After Mixed LOTIS-5 ZYNLONTA Data - Has The Bull Case Changed?June 8, 2026 | finance.yahoo.comSpaceX will crumble without these 5 companiesThe SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate. Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook. | InvestPub (Ad)ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursday's Pre-Market Session (CORRECTED)June 6, 2026 | feeds.benzinga.comADC Therapeutics (NYSE:ADCT) Downgraded to "Sell" Rating by Wall Street ZenJune 6, 2026 | americanbankingnews.comWhy is ADC Therapeutics stock falling Thursday?June 5, 2026 | msn.comADC Therapeutics falls on confirmatory trial data for lymphoma therapyJune 5, 2026 | msn.comADC Therapeutics plunges after patient deaths in blood cancer drug trialJune 4, 2026 | reuters.comSee More Headlines ADCT Stock Analysis - Frequently Asked Questions How have ADCT shares performed this year? ADC Therapeutics' stock was trading at $3.54 at the beginning of 2026. Since then, ADCT shares have decreased by 69.9% and is now trading at $1.0650. How were ADC Therapeutics' earnings last quarter? ADC Therapeutics SA (NYSE:ADCT) announced its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. The company earned $20.85 million during the quarter, compared to the consensus estimate of $19.99 million. Read the conference call transcript. When did ADC Therapeutics IPO? ADC Therapeutics (ADCT) raised $208 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 12,245,631 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO. Who are ADC Therapeutics' major shareholders? ADC Therapeutics' top institutional investors include Redmile Group LLC (12.16%), Bank of America Corp DE (1.04%), Orbimed Advisors LLC (1.04%) and Renaissance Technologies LLC (0.24%). Insiders that own company stock include Redmile Group, Llc, Ameet Mallik and Robert Azelby. View institutional ownership trends. How do I buy shares of ADC Therapeutics? Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADC Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/05/2026Today6/16/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 12 days, ADCT's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSE:ADCT CIK1771910 Webwww.adctherapeutics.com Phone41-21-653-0200FaxN/AEmployees310Year Founded2010Price Target and Rating Average Price Target for ADC Therapeutics$6.25 High Price Target$10.00 Low Price Target$2.00 Potential Upside/Downside+486.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$142.62 million Net Margins-173.02% Pretax Margin-171.95% Return on EquityN/A Return on Assets-44.70% Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio4.02 Sales & Book Value Annual Sales$81.36 million Price / Sales1.66 Cash FlowN/A Price / Cash FlowN/A Book Value($1.50) per share Price / Book-0.71Miscellaneous Outstanding Shares127,190,000Free Float120,323,000Market Cap$135.46 million OptionableOptionable Beta1.77 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NYSE:ADCT) was last updated on 6/16/2026 by MarketBeat.com Staff. From Our PartnersSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredThe Next QualcommPorter Stansberry recommended Qualcomm in 1999 at $4 a share - it climbed more than 5,000%. He found the same ...Porter & Company | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADCT Stock Alerts